<DOC>
	<DOCNO>NCT00011960</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy cisplatin paclitaxel use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Cisplatin paclitaxel may make tumor cell sensitive radiation therapy may kill tumor cell remain surgery . PURPOSE : Randomized phase II trial study effectiveness cisplatin , paclitaxel , radiation therapy without fluorouracil treat patient stage IB , stage IIB , stage IIIB stomach cancer remove surgery .</brief_summary>
	<brief_title>Chemotherapy Radiation Therapy With Without Fluorouracil Treating Patients With Cancer Stomach Who Have Undergone Surgery</brief_title>
	<detailed_description>OBJECTIVES : - Compare 2-year disease-free survival patient resect stage IB-IIIB gastric cancer treat cisplatin , paclitaxel , radiotherapy without fluorouracil v therapy adjuvant arm intergroup adjuvant protocol 0116 ( RTOG 90-18 ) . ( Arm I close accrual 6/18/03 . ) - Compare safety success regimens vs therapy intergroup adjuvant study . - Compare toxic effect regimens vs therapy adjuvant arm intergroup study . OUTLINE : This randomize , multicenter study . Patients stratify accord tumor stage ( T1-2 v T3 v T4 ) number involve lymph node ( none v 1-3 v 4 ) . Patients randomize one two treatment arm . ( Arm I close accrual 6/18/03 . ) - Arm I ( close accrual 6/18/03 ) : Patients receive fluorouracil IV continuously cisplatin IV 1 hour day 1-5 29-33 paclitaxel IV continuously day 1 29 . At 3-4 week completion chemotherapy , patient receive radiotherapy daily fluorouracil IV continuously day 1-5 , 8-12 , 15-19 , 22-26 , 29-33 . Patients also receive paclitaxel IV 3 hour day 1 , 8 , 15 , 22 , 29 . - Arm II : Patients receive paclitaxel IV 3 hour cisplatin IV 1 hour day 1 29 . At 3-4 week completion chemotherapy , patient receive radiotherapy daily paclitaxel IV continuously day 1-5 , 8-12 , 15-19 , 22-26 , 29-33 . Patients also receive cisplatin IV 1 hour day 1 , 8 , 15 , 22 , 29 . Patients follow every 3 month 2 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 94 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage IBIIIB adenocarcinoma stomach gastroesophageal junction undergone potentially curative resection primary tumor No 8 week since primary tumor resection No metastatic disease PATIENT CHARACTERISTICS : Age : Not specify Performance status : Zubrod 01 Life expectancy : Not specify Hematopoietic : WBC ( white blood cell count ) least 4,000/mm^3 Platelet count least 150,000/mm^3 Hepatic : Bilirubin great 1.5 mg/dL AST ( aspartate aminotransferase ) ALT ( alanine amino transferase ) great 2.5 time upper limit normal Renal : BUN ( blood urea nitrogen ) less 30 mg/dL Creatinine great 1.4 mg/dL Creatinine clearance great 50 mL/min Cardiovascular : No New York Heart Association class III IV heart disease No active angina myocardial infarction within past 6 month No history significant ventricular arrhythmia require medication antiarrhythmic No history clinically significant conduction system abnormality Other : No concurrent serious infection uncontrolled would preclude study participation No nonmalignant medical illness uncontrolled would preclude study participation No psychiatric disorder would preclude study participation No active malignancy within past 3 year except nonmelanoma skin cancer carcinoma situ cervix No clinically significant hearing loss Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy treatment field Surgery : See Disease Characteristics Other : No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>stage I gastric cancer</keyword>
	<keyword>stage II gastric cancer</keyword>
	<keyword>stage III gastric cancer</keyword>
	<keyword>stage I esophageal cancer</keyword>
	<keyword>stage II esophageal cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>adenocarcinoma stomach</keyword>
	<keyword>adenocarcinoma esophagus</keyword>
</DOC>